SCHEDULE: Southpoint Funds Disclose 8% Stake in Fennec Pharma

Southpoint Master Fund and related entities have reported an 8.0% beneficial ownership stake in Fennec Pharmaceuticals Inc., holding 2,744,741 common shares.

Summary

• Southpoint Master Fund, LP, along with its related entities (Southpoint Capital Advisors LP, Southpoint Capital Advisors LLC, Southpoint GP, LP, Southpoint GP, LLC) and John S. Clark II, collectively reported beneficial ownership of 2,744,741 common shares of Fennec Pharmaceuticals Inc.
• This represents an 8.0% stake in the company's common shares.
• The ownership percentage is based on 34,153,496 outstanding common shares, as reported by Fennec Pharmaceuticals Inc. in a Prospectus Supplement filed on November 18, 2025.
• The reporting persons share voting and dispositive power over all 2,744,741 shares.
• The filing is an Amendment No. 2, indicating an update to previously disclosed holdings.

Sentiment

Score: 7

Explanation: The disclosure of an 8.0% beneficial ownership by a prominent investment fund like Southpoint Master Fund is generally perceived as a positive signal, reflecting confidence in Fennec Pharmaceuticals Inc.'s value or future prospects.

Positives

• A significant institutional investor, Southpoint Master Fund, LP, holds an 8.0% stake in Fennec Pharmaceuticals Inc., potentially signaling confidence in the company's future prospects.
• The filing indicates a substantial, long-term interest from a sophisticated investment group.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Fennec Pharmaceuticals, a company likely operating in the biotechnology or pharmaceutical sector. Such investments can be viewed positively by the market, suggesting that sophisticated investors see value or potential in the company's pipeline or market position, especially within the competitive and capital-intensive pharmaceutical industry.

Comparison to Industry Standards

• An 8.0% stake by an institutional investor like Southpoint Master Fund is a substantial position, often indicating a high conviction investment. While specific comparable companies or projects are not mentioned in this filing, such a stake is generally considered a strong vote of confidence, particularly in the biotech/pharma sector where development cycles are long and capital requirements are high.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and attract new investors, potentially influencing share price positively.
• Company Management: A large institutional holder may exert influence on corporate strategy and governance, aligning management's focus with long-term shareholder value.

Key Dates

Recommendation

The filing indicates a substantial 8.0% stake by Southpoint Master Fund, a sophisticated institutional investor. While this signals confidence from a major player, a Schedule 13G primarily discloses ownership and does not provide detailed financial performance or strategic updates. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while monitoring future company developments and financial reports for more comprehensive insights.

Keywords

Fennec Pharmaceuticals Inc., Southpoint Master Fund, Institutional Ownership, Beneficial Ownership, Common Shares, Pharmaceuticals, SEC Filing, Schedule 13G, Investment, Equity Stake